BioClin Therapeutics, Inc., Raises $30 Million in Series B Financing Led by Sofinnova Ventures and Ysios Capital

by Ysios Capital

BioClin Therapeutics, Inc., a privately-­‐held clinical stage drug development company developing a first-­‐in-­‐class anti-­‐FGFR3 (fibroblast growth factor receptor 3) monoclonal antibod...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

Alantra advises Precinmac on its acquisi...

by Alantra

This transaction reinforces Alantra’s continued momentum in Aerospac...

Photos Stream